Skip to main content
Article thumbnail
Location of Repository

Relationship of Metabolic Syndrome With Incident Aortic Valve Calcium and Aortic Valve Calcium Progression: The Multi-Ethnic Study of Atherosclerosis (MESA)*

By Ronit Katz, Matthew J. Budoff, Junichiro Takasu, David M. Shavelle, Alain Bertoni, Roger S. Blumenthal, Pamela Ouyang, Nathan D. Wong and Kevin D. O'Brien
Topics: Original Article
Publisher: American Diabetes Association
OAI identifier: oai:pubmedcentral.nih.gov:2661576
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2005). A: Cholesterol feeding increases C-reactive protein and serum amyloid A levels in lean insulin-sensitive subjects.
    2. (2001). Achenbach S: Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation 104:1927–1932,
    3. (1999). BD: Modern Applied Statistics With S-Plus.
    4. (1998). Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. Clin Orthop Relat Res 346:26–37,
    5. (2005). Budoff MJ: Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med 165:858–862,
    6. (2001). Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683–689,
    7. Clinical practice. Aortic stenosis.
    8. (1987). Correlation of serum lipids, calcium, and phosphorus, diabetes mellitus and history of systemic hypertension with presence or absence of calcified or thickened aortic cusps or root in elderly patients.
    9. (2003). DA: MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors.
    10. (1993). Demer LL: Bone morphogenetic protein expression in human atherosclerotic lesions.
    11. (1990). Detrano R: Quantification of coronary artery calcium using ultrafast computed tomography.
    12. (2003). Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries. Circulation 108:472–478,
    13. (2005). Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735–2752,
    14. (2003). DS: The metabolic syndrome, diabetes, and subclinical atherosclerosis assessed by coronary calcium.
    15. (2007). Effect of scanner type on the reproducibility of extracoronary measures of calcifi-cation: the Multi-Ethnic Study of Atherosclerosis. Acad Radiol 14:1043– 1049,
    16. (2009). enzyme inhibitors delay progression of aortic stenosis. Circulation 110:1291–1295,
    17. (1972). Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502,
    18. (1999). FH: Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis 8:254–260,
    19. (2001). FS: Bone formation and inflammation in cardiac valves. Circulation 103:1522–1528,
    20. (2001). Global and societal implications of the diabetes epidemic.
    21. (2001). Goldman ME: Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons.
    22. (2001). Griffin BP: Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation 104:2205–2209,
    23. (2001). Guerci AD: Association of multiple risk factors and insulin resistance with increased prevalence of asymptomatic coronary artery disease by an electron-beam computed tomographic study. Arterioscler Thromb Vasc Biol 21:2051–2058,
    24. (2008). HA: 10-year follow-up of intensive glucose control in type 2 diabetes.
    25. (2007). Hanafusa T: Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits.
    26. (1961). III: Factors of risk in the development of coronary heart disease—six year follow-up experience. The Framingham Study. Ann Intern Med 55:33–50,
    27. (2001). JW: A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease.
    28. (1997). Kessels F: Cardiac valve calcification: characteristics of patients with calcification of the mitral annulus or aortic valve. Heart 78:472–474,
    29. (2001). Koplan JP: The continuing epidemics of obesity and diabetes in the United States.
    30. (2004). Kovanen PT: Induction of local angiotensin IIproducing systems in stenotic aortic valves.
    31. (2006). Kronmal R: Reproducibility of CT measurements of aortic valve calcification, mitral annulus calcification, and aortic wall calcification in the Multi-Ethnic Study of Atherosclerosis. Acad Radiol 13:166–172,
    32. (1994). LL: TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify.
    33. (2006). Metabolic syndrome is associated with faster degeneration of bioprosthetic valves. Circulation 114:I512–I517,
    34. (2005). NA: A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis.
    35. (2006). O’Brien KD: Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis. Circulation 113:2113–2119,
    36. (2002). O’Brien KD: HMG CoA reductase inhibitor (statin) and aortic valve calcium.
    37. (2008). O’Brien KD: Interaction of age with lipoproteins as predictors of aortic valve calcification in the MultiEthnic Study of Atherosclerosis. Arch Intern Med 168:1200–1207,
    38. (2002). O’Brien KD: Reproducibility of electron-beam CT measures of aortic valve calcification. Acad Radiol 9:1122–1127,
    39. (1997). Otto CM: Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study.
    40. (1988). Pearlman AS: Doppler echocardiography in adults with symptomatic aortic stenosis. Diagnostic utility and cost-effectiveness.
    41. (2006). Pibarot P: Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis.
    42. (1999). Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 19:1218–1222,
    43. (2002). Probstfield JL: Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 106:2224–2230,
    44. (2002). Robust Statistics With the S-Plus Robust Library and Financial Applications.
    45. (2002). RP: Multi-Ethnic Study of Atherosclerosis: objectives and design.
    46. (2002). Salonen JT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.
    47. (1997). Schwaegler RG: Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation 95:2262–2270,
    48. (1999). Siscovick DS: Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly.
    49. (2000). Thorpe SR: Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 28:1708–1716,
    50. (2002). WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.
    51. (2008). Willenheimer R: Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
    52. (2005). Zimmet PZ: The metabolic syndrome. Lancet 365:1415–1428,

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.